

SonixEmbrace Research: breakthrough ultrasound technology for cancer research

Using a patented 360 degree rotating concave ultrasound transducer, SonixEmbrace Research captures realistic, uncompressed images of a breast, while the patient lies in a comfortable, prone position. Integrated with the Ultrasonix Research platform, the system captures gigabytes of raw data, which is ideal for cancer detection research and treatment monitoring.

Realistic breast images help diagnosis

SonixEmbrace is designed to capture natural, uncompressed images of the breast. The patient lies face forward on the bed while the rotating ultrasound transducer captures up to 800 slices of ultra high resolution images. Once collected the data from the scans is downloaded to the ultrasound platform in raw RF or B image format. Volumes may also be rendered in 3D viewing software or on a stand-alone desktop application.


Fast and reproducible breast imaging

SonixEmbrace automatically captures high resolution images of a full breast in two to four minutes. Compared to freehand ultrasound systems, the SonixEmbrace system is at least five times faster and less prone to imaging variations caused by differences in scanning methods.




SonixEmbrace captures natural, uncompressed images of the breast


A rotating ultrasound transducer captures up to 800 slices of ultra high resolution images.



Sagittal View



Coronal View



Transverse View

Gigabytes of raw ultrasound data support new cancer detection methods

With the ability to capture raw B mode images and 16 bit RF data, applying new cancer detection algorithms such as elastography has never been easier. The SonixDAQ plugs into the Ultrasonix research platform to capture pre-beamformed volumetric images from for photoacoustic applications as well (Ultrasonix does not provide laser setup) downloaded to the ultrasound platform in raw RF or B image format. Volumes may also be rendered in 3D viewing software or on a stand-alone desktop application.

Monitor cancer treatment

The Ultrasonix research platform supports the novel technique of monitoring cell death, which allows researchers to determine the success of treatment within as little as one to four weeks.

Fusion imaging provides a more complete picture

Data from the SonixEmbrace can be integrated with Computed Tomography (CT) and Magnetic Resonance (MR) imaging to provide a more complete picture of the breast.



About Ultrasonix:

Ultrasonix has been a leading provider of dynamic ultrasound research systems for biomedical and pre-clinical research for more than 10 years. The company also develops and manufactures diagnostic ultrasound imaging systems for clinical use. Ultrasonix systems are built on an open software platform that enables remote service and easy updates to keep current with advancements in imaging technology. Founded in 2000, the company is privately-held and headquartered in Richmond, British Columbia, Canada.

Email: info@ultrasonix.com / **Call Toll Free in North America:** 1-866-437-9508 / **Web:** www.ultrasonix.com/Research

© Ultrasonix Medical Corporation — All rights reserved. 00.050.172 Rev A
Ultrasonix™ is a trademark of Ultrasonix Medical Corporation. SonixEmbrace is not currently approved for clinical applications or screening purposes. Ultrasonix Medical Corporation reserves the right to make changes in specifications, physical appearance and features and/or to discontinue any product at any time without notice or obligation. These materials do not contain complete information on Ultrasonix's products and should not be relied upon in using our products. Please contact us for technical information and materials for each product. We will not be held liable for any consequences that result from using this publication.

